Aprepitant reduces the AUC of
tolbutamide by about 25%. Fosaprepitant is a prodrug of
aprepitant and would be expected to interact similarly.
As the
clinical relevance of this reduction has not been assessed the manufacturer advises caution, but changes of this magnitude are rarely clinically significant.